MYC and diffuse large B-cell lymphoma: Rearrangements of the oncogenes BCL6, BCL2, as well as MYC are well documented in DLBCL, and MYC translocations are recognized to confer a worse prognosis in patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), with or without rituximab (R) [17–20].